Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,084 recruiting studies in this area right now.
By phase
- Not applicable2,111
- Phase 21,115
- Phase 1823
- Phase 1/Phase 2481
- Phase 3348
- Phase 4127
- Phase 2/Phase 379
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia122
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema50
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center64
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California407
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida110
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,084 total
- NCT07008885RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed/refractory B-ALL
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
Beijing, Biotherapeutic Department of Chinese PLA General HospitalAges 18–70 - NCT07009002RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed B-cell lymphoma
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07011004RecruitingPhase 1
NK cells plus atezolizumab for acute myeloid leukemia
This trial tests combining natural killer (NK) immune cells with an immunotherapy drug (atezolizumab) for people with acute myeloid leukemia (AML) that didn't respond to or came back after prior treatments. It aims to see if this combination can help the body fight the leukemia.
Basking Ridge, New JerseyAges 18–70 - NCT07011056RecruitingPhase 3
Study of a new drug for diffuse large B-cell lymphoma
This trial tests a new drug called Purinostat Mesylate for people with diffuse large B-cell lymphoma (a type of blood cancer) whose cancer has come back or not responded after at least two prior treatments. It aims to see if the drug can help shrink or control the cancer.
Chengdu, SichuanAges 18 years+ - NCT07011316Recruiting
Preventing lymphedema in cancer patients through monitoring
This trial tests whether a simple standing test can help spot early signs of lymphedema (swelling) in cancer patients. If you are being treated at the Greater Poland Cancer Centre, you may be able to help doctors learn how to prevent this side effect.
Poznan, Greater Poland VoivodeshipAges 18 years+ - NCT07011966Recruiting
A breathing therapy for insomnia
This trial tests a new type of breathing therapy (ASV) for people with insomnia. It looks at whether the therapy can help you fall asleep and stay asleep better.
Detroit, MichiganAges 18 years+ - NCT07012447RecruitingPhase 2
Venetoclax with azacytidine for newly diagnosed T-cell leukemia
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
Suzhou, JiangsuAges 14 years+ - NCT07012642RecruitingEarly Phase 1
GLP-1 drugs for arm or leg swelling (lymphedema)
This trial tests if a class of diabetes drugs (GLP-1 receptor agonists) can reduce swelling in one arm or leg caused by lymphedema. It may help people who have not found relief from other treatments.
Red Bank, New JerseyAges 18 years+ - NCT07012928Recruiting
Study of immune responses in eosinophilic esophagitis patients
This study looks at how the immune system and the esophageal barrier function in people with eosinophilic esophagitis (EoE) compared to those without. It involves taking biopsies during an upper endoscopy to understand the disease better. The results may help improve treatments for EoE.
Amsterdam, North HollandAges 18–75 - NCT07013565RecruitingPhase 2
Chemoimmunotherapy for ALK+ ALCL that has come back
This trial tests a combination of chemotherapy and immunotherapy for children and adults with a type of lymphoma called ALK-positive anaplastic large cell lymphoma that has returned or not responded to previous treatment. The goal is to see if this new approach can help control the disease.
Valhalla, New YorkAges 1–39 - NCT07014319RecruitingPhase 2
Maribavir for CMV in lymphoma patients on bispecific antibodies
This trial tests a new drug, maribavir, for controlling or treating active CMV infection in people with certain blood cancers (multiple myeloma, follicular lymphoma, or large B-cell lymphoma) who are taking a bispecific antibody therapy. The goal is to see if maribavir is safe and effective for managing CMV in this specific situation.
SeoulAges 19 years+ - NCT07014449RecruitingPhase 1
WBC100 capsule for relapsed or refractory AML
This trial tests an experimental capsule called WBC100 for people whose leukemia has come back or hasn't responded to standard treatments. It aims to see if the drug is safe and if it can help control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07014371Recruiting
Iron pills: every other day vs. daily
This trial tests whether taking iron pills every other day works as well as taking them every day. It is for people with iron deficiency anemia who have not used iron recently.
BangkokAges 20 years+ - NCT07014865Recruiting
Quality of life and social participation in multiple myeloma patients and caregivers
This study looks at how multiple myeloma and its treatment affect the daily life, well-being, and social activities of patients and their caregivers. It aims to understand what factors influence their quality of life.
Reggio Emilia, REAges 18 years+ - NCT07014917RecruitingPhase 2
Comparing two ways to take venetoclax and acalabrutinib for CLL/SLL
This trial tests whether taking venetoclax on an intermittent schedule (not every day) works as well as taking it continuously when combined with acalabrutinib for people with untreated CLL or SLL. It aims to find a treatment approach that might be just as effective but with fewer side effects.
Cincinnati, OhioAges 18 years+ - NCT07015684RecruitingPhase 1
Radioactive antibody and transplant for advanced sickle cell disease
This trial tests a radioactive antibody (131I-apamistamab) as part of conditioning before a stem cell transplant from a matched sibling donor. It aims to make the transplant safer and more effective for people with severe sickle cell disease.
New York, New YorkAges 12–50 - NCT07016165RecruitingPhase 4
Comparing two antibiotics for fever with low white blood cells in children with blood cancer
This trial compares two antibiotics, ciprofloxacin and ceftazidime, to see which works better for treating fever in children with blood cancer who have a high risk of infection due to low white blood cells. The goal is to find the best treatment to help your child recover faster.
Sleman, DI YogyakartaAges Up to 18 years - NCT07017725RecruitingPhase 1/Phase 2
Testing a new drug for chronic low platelets
This trial tests an investigational drug called CID-103 for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. It aims to find the right dose and see if it can safely increase platelet counts to reduce bleeding risk.
Tangshan, HebeiAges 18–65 - NCT07018050RecruitingPhase 2
A study of a new combination for multiple myeloma
This study tests a new combination therapy for people with multiple myeloma that has returned or not responded to at least one prior treatment. The goal is to see if the combination (QLS32015 plus other drugs) can effectively control the cancer.
TianjinAges 18 years+ - NCT07018752RecruitingPhase 1/Phase 2
Testing new drug combos for relapsed T-cell lymphoma
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
CaenAges 18 years+ - NCT07019038Recruiting
Autoimmune hemolytic anemia long-term study
This study looks at people with autoimmune hemolytic anemia (AIHA) over time. It aims to understand the disease better and find ways to improve care.
Tianjin, Tianjin MunicipalityAges Any age - NCT07019155Recruiting
DDX41 gene study for families with cancer risk
This study looks at people and families who have changes in the DDX41 gene or similar genes that may increase the risk of cancer. By joining, you can help researchers learn more about these gene changes and how they affect health.
Bethesda, MarylandAges 1 month–120 years - NCT07019766Recruiting
Long-term study of LGLL leukemia patients
This study follows people with large granular lymphocytic leukemia (LGLL) over time to learn more about the disease. It collects information from patients treated at the Institute of Hematology and Blood Diseases Hospital in China.
Tianjin, Tianjin MunicipalityAges Any age - NCT07021495Recruiting
Skin disease study to improve treatment choices
This study looks at different skin diseases to find markers that can help guide treatment. It tests new treatments for several conditions like eczema, psoriasis, and lupus, with the goal of personalizing care.
Nijmegen, GelderlandAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,084 recruiting hematology studies from the U.S. registry right now, out of 7,742 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.